Min Zhang

Min Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MZMei Zhao
Mei Zhao
PWPengjiao Wang
Pengjiao Wang
XSXiaodong Sun
Xiaodong Sun
DYDan Yang
Dan Yang
SZShuo Zhang
Shuo Zhang
XGXiuli Gao
Xiuli Gao
Polyethylene glycol 400 (PEG400) is a widely used pharmaceutical excipient in the field of medicine. It not only enhances the dispersion stability of the main drug but also facilitates the absorption of multiple drugs. Our previous study found that the long-term application of PEG400 as an adjuvant in traditional Chinese medicine preparations resulted in wasting and weight loss in animals, which aroused our concern. In this study, 16S rRNA high-throughput sequencing technology was used to analyze the diversity of gut microbiota, and LC-MS/MS Q-Exactive Orbtriap metabolomics technology was used to analyze the effect of PEG400 on the metabolome of healthy mice, combined with intestinal pathological analysis, aiming to investigate the effects of PEG400 on healthy mice. These results showed that PEG400 significantly altered the structure of gut microbiota, reduced the richness and diversity of intestinal flora, greatly increased the abundance of Akkermansia muciniphila (A. muciniphila), increased the proportion of Bacteroidetes to Firmicutes, and reduced the abundance of many beneficial bacteria. Moreover, PEG400 changed the characteristics of fecal metabolome in mice and induced disorders in lipid and energy metabolism, thus leading to diarrhea, weight loss, and intestinal inflammation in mice. Collectively, these findings provide new evidence for the potential effect of PEG400 ingestion on a healthy host.

8 August 2022 in Foods
Verified
Journal Article
Open access
PDF file
XSXiaodong Sun
Xiaodong Sun
MZMin Zhang
Min Zhang
PWPengjiao Wang
Pengjiao Wang
JCJunhua Chen
Junhua Chen
SYShengjun Yang
Shengjun Yang
XGXiuli Gao
Xiuli Gao
Paprika is a widely consumed spice in the world and its authentication has gained interest considering the increase in adulteration cases in recent years. In this study, second-order fingerprints acquired by liquid chromatography with fluorescence detection (HPLC-FLD) were first used to detect and quantify adulteration levels of Chinese paprika samples. Six different adulteration cases, involving paprika production region, cultivar, or both, were investigated by pairs. Two strategies were employed to reduce the data matrices: (1) chromatographic fingerprints collected at specific wavelengths and (2) fusion of the mean data profiles in both spectral and time dimensions. Afterward, the fingerprint data with different data orders were analyzed using partial least squares (PLS) and n-way partial least squares (N-PLS) regression models, respectively. For most adulteration cases, N-PLS based on second-order fingerprints provided the overall best quantitation results with cross-validation and prediction errors lower than 2.27% and 20.28%, respectively, for external validation sets with 15–85% adulteration levels. To conclude, second-order HPLC-FLD fingerprints coupled with chemometrics can be a promising screening technique to assess paprika quality and authenticity in the control and prevention of food frauds.

Verified
Journal Article
Open access
PDF file
CLChaoji Li
Chaoji Li
MZMin Zhang
Min Zhang
YZYanni Zhao
Yanni Zhao
DYDan Yang
Dan Yang
MZMei Zhao
Mei Zhao
XGXiuli Gao
Xiuli Gao
Mycophenolic acid (MPA) is a commonly used immunosuppressant. In the human body, MPA is metabolized into mycophenolic acid 7-O-glucuronide (MPAG) and mycophenolic acid acyl-glucuronide (AcMPAG) mainly through liver glucuronidation, which involves UDP-glucuronosyltransferase (UGTs) and transfer proteins. Research has indicated that the pharmaceutical excipient PEG400 can impact drug processes in the body, potentially affecting the pharmacokinetics of MPA. Due to the narrow therapeutic window of MPA, combination therapy is often used, and PEG400 is widely used in pharmaceutical preparations. Therefore, investigating the pharmacokinetic influence of PEG400 on MPA could offer valuable insights for optimizing MPA’s clinical use. In this study, we examined the impact of a single oral dose of PEG400 on the blood levels of MPA in rats through pharmacokinetic analysis. We also investigated the distribution of MPA in various tissues using mass spectrometry imaging. We explored the potential mechanism by which PEG400 affects the metabolism of MPA using hepatic and intestinal microsomes and the Caco-2 cellular transporter model. Our findings reveal that the overall plasma concentrations of MPA were elevated in rats following the co-administration of PEG400, with the AUC0-t of MPA and its metabolite MPAG increasing by 45.53% and 29.44%, respectively. Mass spectrometry imaging showed increased MPA content in tissues after PEG400 administration, with significant differences in the metabolites observed across different tissues. Microsomal and transport experiments showed that PEG400 accelerated the metabolism of MPA, promoted the uptake of MPA, and inhibited efflux. In conclusion, PEG400 alters the in vivo metabolism of MPA, potentially through the modulation of metabolic enzymes and transport.

28 July 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
DMDuo Meng
Duo Meng
PWPengjiao Wang
Pengjiao Wang
SZShuo Zhang
Shuo Zhang
ZCZhiyu Chen
Zhiyu Chen
CLChencen Lai
Chencen Lai
XGXiuli Gao
Xiuli Gao
Hyperlipidemia has become a prevalent disease in the global epidemic, posing a threat to human health. This study aims to investigate the mechanism by which Rosa roxburghii fermented juice (RRFJ) can prevent lipid deposition induced by a high‐fat diet in mice. The results showed that mice in the RRFJ intervention group had significantly reduced body weight as well as lower levels of serum and liver lipid indicators compared to the high‐fat diet group. Metagenomic analysis revealed that the RRFJ intervention reversed the decrease in intestinal flora Alistipes and Colidextribacter genes in mice fed a high‐fat diet. Liver metabolomics showed that the RRFJ prevented liver dyslipidemia by modulating the biosynthesis of phenylalanine, tyrosine, tryptophan, and phenylalanine metabolism. RRFJ is effective in preventing dyslipidemia through the ‘gut‐liver axis’, which regulates the imbalance of intestinal flora and improves hepatic metabolic profiles. This provides a new intervention strategy for the prevention and treatment of hyperlipidemia.

30 April 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
ZCzhiyu Chen
zhiyu Chen
SZShuo Zhang
Shuo Zhang
XSXiaodong Sun
Xiaodong Sun
MDMeng Duo
Meng Duo
CLChencen Lai
Chencen Lai
XGXiuli Gao
Xiuli Gao
Acute lung injury, a fatal condition characterized by a high mortality rate, necessitates urgent exploration of treatment modalities. Utilizing UHPLS-Q-Exactive Orbitrap/MS, our study scrutinized the active constituents present in Rosa roxburghii-fermented juice (RRFJ) while also assessing its protective efficacy against LPS-induced ALI in mice through lung histopathological analysis, cytokine profiling, and oxidative stress assessment. The protective mechanism of RRFJ against ALI in mice was elucidated utilizing metabolomics, network pharmacology, and molecular docking methodologies. Our experimental findings demonstrate that RRFJ markedly ameliorates pathological injuries in ALI-afflicted mice, mitigates systemic inflammation and oxidative stress, enhances energy metabolism, and restores dysregulated amino acid and arachidonic acid metabolic pathways. This study indicates that RRFJ can serve as a functional food for adjuvant treatment of ALI.

29 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DYDan Yang
Dan Yang
MZMin Zhang
Min Zhang
MZMei Zhao
Mei Zhao
CLChaoji Li
Chaoji Li
LSLeyuan Shang
Leyuan Shang
XGXiuli Gao
Xiuli Gao
Pharmaceutical excipient PEG400 is a common component of traditional Chinese medicine compound preparations. Studies have demonstrated that pharmaceutical excipients can directly or indirectly influence the disposition process of active drugs in vivo, thereby affecting the bioavailability of drugs. In order to reveal the pharmacokinetic effect of PEG400 on baicalin in hepatocytes and its mechanism, the present study first started with the effect of PEG400 on the metabolic disposition of baicalin at the hepatocyte level, and then the effect of PEG400 on the protein expression of baicalin-related transporters (BCRP, MRP2, and MRP3) was investigated by using western blot; the effect of MDCKII-BCRP, MDCKII-BCRP, MRP2, and MRP3 was investigated by using MDCKII-BCRP, MDCKII-MRP2, and MDCKII-MRP3 cell monolayer models, and membrane vesicles overexpressing specific transporter proteins (BCRP, MRP2, and MRP3), combined with the exocytosis of transporter-specific inhibitors, were used to study the effects of PEG400 on the transporters in order to explore the possible mechanisms of its action. The results demonstrated that PEG400 significantly influenced the concentration of baicalin in hepatocytes, and the AUC0–t of baicalin increased from 75.96 ± 2.57 μg·h/mL to 106.94 ± 2.22 μg·h/mL, 111.97 ± 3.98 μg·h/mL, and 130.42 ± 5.26 μg·h/mL (p ˂ 0.05). Furthermore, the efflux rate of baicalin was significantly reduced in the vesicular transport assay and the MDCKII cell model transport assay, which indicated that PEG400 had a significant inhibitory effect on the corresponding transporters. In conclusion, PEG400 can improve the bioavailability of baicalin to some extent by affecting the efflux transporters and thus the metabolic disposition of baicalin in the liver.